Efficacy and safety of ruxolitinib plus extracorporeal photopheresis in acute and chronic graft versus host disease: A single center experience

Basit Öğe Kaydı
dc.contributor.authorSarici, Ahmet
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorBahcecioglu, Omer Faruk
dc.contributor.authorTanriverdi, Lokman Hekim
dc.contributor.authorBerber, İlhami
dc.contributor.authorKaya, Emin
dc.contributor.authorBiçim, Soykan
dc.contributor.authorGok, Selim
dc.contributor.authorÖzgül, Mustafa
dc.contributor.authorKuku, İrfan
dc.date.accessioned2022-02-08T07:36:59Z
dc.date.available2022-02-08T07:36:59Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAbstract: Aim: There is no standard treatment for corticosteroid refractory acute and chronic graft versus host disease (GVHD). Ruxolitinib and extracorporeal phopheresis (ECP) are promising treatment options in GVHD. In this study, we aimed to share our clinical experience in steroid refractory GVHD patients treated with ruxolitinib plus ECP. Materials and Methods: The data of patients receiving ruxolitinib plus ECP for corticosteroid refractory acute and chronic GVHD patients were analyzed retrospectively. Results: A total of 11 cases, 6 of which were acute, were included in this retrospective, observational and single-center study. Acute GVHD developed in the 6 patients after allogeneic HSCT (median onset of GVHD=27, between 20 and 60 days ). Chronic GVHD developed in the 5 patients after allogeneic HSCT (median onset of GVHD= 159 between 60 and 380 days. The overall response rate of acute GVHD patients to ruxolitinib ECP combination therapy was 16.7% (complete response: 16.7%, partial response: 0%). The overall response rate of chronic GVHD patients to combination therapy was 60% (complete response: 20%, partial response: 40%). As a result of combination therapy, thrombocytopenia occurred in 36% (4/11) of patients, neutropenia in 27% (3/11) of patients, and CMV reactivation in 9% (1/11) of patients. Conclusion: We observed a low rate of overall response to ruxolitinib plus ECP treatment in acute GVHD patients but a high rate in chronic GVHD patients. According to our trial, ruxolitinib ECP combination may be beneficial in GVHD, especially in chronic GVHD, but prospective trials comparing its efficacy with other agents are needed.en_US
dc.identifier.citationSARİCİ A,ERKURT M. A,BAHCECİOGLU O. F,TANRİVERDİ L. H,BERBER I,KAYA E,BİCİM S,GOK S,OZGUL M,KUKU I (2021). Efficacy and safety of ruxolitinib plus extracorporeal photopheresis in acute and chronic graft versus host disease: A single center experience. Annals of Medical Research, 28(11), 2065 - 2070.en_US
dc.identifier.doi10.5455/annalsmedres.2021.03.206en_US
dc.identifier.endpage2070en_US
dc.identifier.issn2636-7688
dc.identifier.issue11en_US
dc.identifier.startpage2065en_US
dc.identifier.trdizinid482789en_US
dc.identifier.urihttps://doi.org/10.5455/annalsmedres.2021.03.206
dc.identifier.urihttps://hdl.handle.net/11616/46797
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/482789
dc.identifier.volume28en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleEfficacy and safety of ruxolitinib plus extracorporeal photopheresis in acute and chronic graft versus host disease: A single center experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
89176730-ee3e-47cf-b434-6f614c2aa807.pdf
Boyut:
158.95 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu